ADMA (ADMA Biologics) Net Issuance of Debt : $-53.6 Mil (TTM As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. ADMA Biologics's net issuance of debt for the three months ended in Sep. 2024 was $-30.0 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Sep. 2024 was $-53.6 Mil.

ADMA Biologics Net Issuance of Debt Historical Data

The historical data trend for ADMA Biologics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADMA Biologics Net Issuance of Debt Chart

ADMA Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

Get a 7-Day Free Trial

42.47

13.52

-0.03

51.71

-23.60

ADMA Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Issuance of Debt	Get a 7-Day Free Trial															-	-23.59	-	-	-30.00

ADMA Biologics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.6 Mil.

ADMA Biologics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of ADMA Biologics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

ADMA Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

465 State Route 17, Ramsey, NJ, USA, 07446

Website

https://www.admabiologics.com

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Executives

Adam S Grossman	director, officer: President and CEO	65 COMMERCE WAY, HACKENSACK NJ 07601
Lawrence P. Guiheen	director	65 COMMERCE WAY, HACKENSACK NJ 07601
Jerrold B Grossman	director	65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon	director	C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Steve Elms	director	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alison Cecily Finger	director	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Brian Lenz	officer: EVP, CFO	65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond	officer: CSO/CMO	65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust	10 percent owner	C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854